Last update 26 Jun 2025

Odronextamab

Overview

Basic Info

Drug Type
Bispecific T-cell Engager (BiTE)
Synonyms
CD20xCD3 bispecific antibody, Odronextamab (USAN), REGN-1979
+ [4]
Action
inhibitors, stimulants
Mechanism
CD20 inhibitors(B-lymphocyte antigen CD20 inhibitors), CD3 stimulants(T cell surface glycoprotein CD3 stimulants), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects)
Inactive Indication-
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
RegulationPriority Review (United States), Fast Track (United States), Orphan Drug (United States), Orphan Drug (European Union)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D11534---

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Diffuse large B-cell lymphoma recurrent
European Union
22 Aug 2024
Diffuse large B-cell lymphoma recurrent
Iceland
22 Aug 2024
Diffuse large B-cell lymphoma recurrent
Liechtenstein
22 Aug 2024
Diffuse large B-cell lymphoma recurrent
Norway
22 Aug 2024
Diffuse large B-cell lymphoma refractory
European Union
22 Aug 2024
Diffuse large B-cell lymphoma refractory
Iceland
22 Aug 2024
Diffuse large B-cell lymphoma refractory
Liechtenstein
22 Aug 2024
Diffuse large B-cell lymphoma refractory
Norway
22 Aug 2024
Recurrent Follicular Lymphoma
European Union
22 Aug 2024
Recurrent Follicular Lymphoma
Iceland
22 Aug 2024
Recurrent Follicular Lymphoma
Liechtenstein
22 Aug 2024
Recurrent Follicular Lymphoma
Norway
22 Aug 2024
Refractory Follicular Lymphoma
European Union
22 Aug 2024
Refractory Follicular Lymphoma
Iceland
22 Aug 2024
Refractory Follicular Lymphoma
Liechtenstein
22 Aug 2024
Refractory Follicular Lymphoma
Norway
22 Aug 2024
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Aggressive B-Cell Non-Hodgkin LymphomaPhase 3
United States
15 Feb 2024
Aggressive B-Cell Non-Hodgkin LymphomaPhase 3
Australia
15 Feb 2024
Aggressive B-Cell Non-Hodgkin LymphomaPhase 3
Italy
15 Feb 2024
Aggressive B-Cell Non-Hodgkin LymphomaPhase 3
Malaysia
15 Feb 2024
Aggressive B-Cell Non-Hodgkin LymphomaPhase 3
Netherlands
15 Feb 2024
Aggressive B-Cell Non-Hodgkin LymphomaPhase 3
Singapore
15 Feb 2024
Aggressive B-Cell Non-Hodgkin LymphomaPhase 3
Spain
15 Feb 2024
Aggressive B-Cell Non-Hodgkin LymphomaPhase 3
Taiwan Province
15 Feb 2024
Aggressive B-Cell Non-Hodgkin LymphomaPhase 3
Thailand
15 Feb 2024
Aggressive B-Cell Non-Hodgkin LymphomaPhase 3
Turkey
15 Feb 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
157
zxqamhkeee(rblmqrdzms) = sfqajjkfdt fkwclorbzb (mitzxmyvyv )
Positive
30 May 2025
Not Applicable
386
ffxvpdaneo(ojmkmnrssf) = 41% hwwmglxvep (plxwdwekot )
Positive
30 May 2025
Phase 2
Refractory Follicular Lymphoma
Maintenance
CD20 | CD3
157
rxpzmhdflg(btrmdrgpek) = vhrulqsior zpemldclmq (nfysmfrfpy )
Positive
22 May 2025
Phase 2
Follicular Lymphoma
IFN-γ | IL-6 | PD1 ...
-
(Marginal Zone Lymphoma (MZL))
jfebwrnwbb(zelydrsmyv) = txyliakskw kzfwxoplqn (mpdqzvjbxm )
-
14 May 2025
(Follicular Lymphoma (FL))
jfebwrnwbb(zelydrsmyv) = phcjjxztxq kzfwxoplqn (mpdqzvjbxm )
Phase 2
121
dfznzkckrm(lsagmmdzlo) = 68% and 65% rrclcaplfm (tirmijalzl )
-
14 May 2025
Phase 2
127
keahaiiwgl(iblbywnoef) = ltasowxtrl zknhrwuhac (yisclooali )
Positive
17 Mar 2025
Phase 2
128
uakxwhsfbk(ydyrzjxmae) = lygnfkozbw ljggflingh (jkjunzxryu )
Positive
14 May 2024
Phase 1
44
jnisnfkzwm(finmhsqpxq) = ptdxmueslg tsddeehnao (rbvmtckcru )
Positive
14 May 2024
Phase 1/2
507
Odronextamab 80 mg QW
omazfdrexk(vqfvmlpqfl) = qeiijvtsxm tivqqjkplk (stcnjjcwvm )
Positive
14 May 2024
Odronextamab 160 mg QW
omazfdrexk(vqfvmlpqfl) = lnumpwcycm tivqqjkplk (stcnjjcwvm )
Phase 2
Follicular Lymphoma | Refractory Follicular Lymphoma | Diffuse Large B-Cell Lymphoma ...
ctDNA | MRD | MYC/BCL2/BCL6 rearrangement ...
-
pttbjllstf(mccprlsvtm) = yobcjarhfh jyoxurvent (uuyxzzrjll )
Positive
14 May 2024
Placebo
pttbjllstf(mccprlsvtm) = qcamtjrrjm jyoxurvent (uuyxzzrjll )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free